Abstract: Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (M-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

Abstract: Provided herein is a process for resolving the (S)- and (R)- enantiomers of a compound of Formula (I), wherein L, R1, and R2 are defined herein.

Abstract: A composition including N,N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof capable of exhibiting a therapeutically effective blood level of DMT from between about 20 and about 60 minutes when administered to a human. A method of treating a neurological disease or condition comprising administering buccally, sublingually, subcutaneously or intranasally to a subject in need thereof an effective amount of DMT or a pharmaceutically acceptable salt thereof, capable of exhibiting a therapeutically effective level of DMT from for between about 20 to about 60 minutes when administered to a human.